Welcome!

News Feed Item

Blood-Brain Barrier Technologies and Global Markets

NEW YORK, Aug. 11, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Blood-Brain Barrier Technologies and Global Markets

http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html

This BCC Research report analyzes the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are also discussed. This report offers an outlook of the technology's potential that is on the verge of rapid increase.

Use this report to:
- Determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its growth potential over a five-year period from 2014
through 2019.
- Receive information about the key drivers and key challenges involved in BBB technologies.
- Receive information about the promising CNS drugs that are in the later stage of the development pipeline for potential use with BBB technology.
- Learn about key BBB technology patents.

Highlights
- The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
- Receptor mediated transport is the largest segment of the global BBB market and is projected to increase from about $38.7 million in 2014 to $456 million by 2019, with a CAGR of 63.8% for the period of 2014 to 2019.
- Carrier-mediated transport (CMT) is an emerging technology that is expected to reach $15.5 million by 2019.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
BCC Research's goal in conducting this study was to determine the current status of the global therapeutic market for blood-brain barrier (BBB) technologies, including its
growth potential over a five-year period from 2014 through 2019. Our key objective was to present a comprehensive analysis of the current BBB technology and drug
development market and its future direction, with the aim to first define and classify that technology as it pertains to therapeutics in which the technology enables the
therapeutic to directly cross rather than bypass the BBB.

REASONS FOR DOING THIS STUDY
BBB technologies are poised to open up a vast untapped potential in the growing central nervous system therapeutic market, where today growth is limited by the
complexity of this layer in the brain that prevents the passage of many potentially useful molecules/compounds. This report offers an outlook of the technology's potential that is on the verge of rapid increase. Therapeutics make up the main area of investment related to this technology — and the main focus of this report. BCC Research has not yet examined the BBB, although the central nervous system has been a consistent focus. As such, this snapshot and study of trending and growth is unique.

SCOPE OF REPORT
The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development, in which a quality of the development
is enabling the crossing of the BBB, where passage was previously impossible often due to size. BCC Research analyzes each technology, determines its current market
status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

INTENDED AUDIENCE
In the report, the various BBB technologies are defined and given their history in medicine. The report also looks at the types and technology categories, major companies, impact on the pharmaceutical market, applications, current market values, growth potential and significant trends. This study will be of interest to the biotechnology and pharmaceutical industries and related life sciences, analytics, drug discovery, and diagnostic test manufacturing companies, as well as all those interested or actively working in drug and imaging agent research and investors in all of the above.

METHODOLOGY
BCC Research presents an analysis of the types of technologies, applications, and therapeutic areas representing financial value in the area of BBB technology in medicine as it relates primarily to drug discovery, development, and commercialization. Estimated values are based on actual aggregate sales for the years discussed. Overall, information is compiled through a combination of primary and secondary research, including annual reports and interviews with company officials.

INFORMATION SOURCES
BCC Research's analysis includes the review of more than 50 companies and information from financial and trade publications, as well as the US Food and Drug Administration (FDA). Pharmaceutical and biotechnology companies, as well as support companies, are also included.
TABLE OF CONTENTS
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THIS STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 2
METHODOLOGY 3
INFORMATION SOURCES 3
ANALYST'S CREDENTIALS 3
RELATED BCC RESEARCH REPORTS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4
CHAPTER 2 EXECUTIVE SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
THROUGH 2019 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS) 7
EMERGING BBB TECHNOLOGY MARKET 10
KEY DRIVERS 12
KEY CHALLENGES 13
CHAPTER 3 OVERVIEW 15
MAJOR TRENDS 15
TODAY'S PHARMA MARKET 16
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION,
THROUGH 2017 ($ BILLIONS) 17
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND
2017 (PERCENT OF GLOBAL SALES) 18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO
THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS) 18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
REGION, 2019* ($ MILLIONS) 19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS) 20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%) 21
BIOLOGICS 22
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013 22
GENERICS SIGNAL NEED FOR INNOVATION 24
NEUROFOCUSING IN THE PHARMA INDUSTRY 24
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS) 24
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 (NUMBER OF UNITS COMMERCIALIZED) 26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION) 26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS) 27
EMERGING BBB TECHNOLOGY MARKET 28
BRIEF HISTORY OF BBB 29
BLOOD BRAIN BARRIER DEFINED 29
BBB COMPONENTS 30
Pericytes 30
Tight Junctions 31
Lipid Barrier 31
Enzymatic Barrier 31
Efflux Pumps 31
BBB ILLUSTRATED 31
FIGURE 7 PARTS OF THE BBB 31
MAIN AREAS OF THE BRAIN 32
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS 32
TREATING DISEASE AND THE BBB 34
MENINGITIS 34
MULTIPLE SCLEROSIS (MS) 34
ENCEPHALITIS 35
ALZHEIMER'S DISEASE (AD) 35
PARKINSON'S DISEASE (PD) 36
BBB TECHNOLOGY CLASSIFICATION 37
MOST COMMON BBB TECHNOLOGY 37
CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED 38
TRANSPORT CONSIDERATIONS 39
Bypassing the BBB 39
BBB TECHNOLOGY DETAILED 39
Chemical Transport Systems 40
Biological Carrier or Transport Systems 40
Physical Force (Energetic) Opening Through Sound Waves (Targeted
Ultrasound) 41
Enhancing Biological Transport System Techniques 42
FIGURE 9 METHODS OF CROSSING THE BBB 42
Nanoparticles and Liposomes 43
Nanoparticles 43
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY 44
Challenges with Nanoparticles 45
Liposomes 45
PATENTS AND INTELLECTUAL PROTECTION 47
TABLE 7 KEY BBB TECHNOLOGY PATENTS 48
ArmaGen's Patent Estate 50
Life After Patenting 53
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013 54
BBB TECHNOLOGY MARKET: PRESENT AND FUTURE 54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS) 55
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY) 56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET) 56
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014
AND 2019 (NUMBER OF UNITS) 58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL
METHOD 59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING
DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET 61
Genzyme Innovates and Sells Technology to Pharmidex 61
DRUG DEVELOPMENT IN THE CNS 62
Multiple Models Must Be Used 62
BBB Is Its Own Site of Investigation 63
Understanding Interactions and Brain Areas as Distinct 64
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB
TECHNOLOGIES 64
What Values Are Best 66
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS 67
PROMISING RESEARCH 67
PROMISING CNS DRUGS THAT ARE LATER STAGE IN THE DEVELOPMENT
PIPELINE FOR POTENTIAL USE WITH BBB TECHNOLOGY 70
Brain Cancer 70
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019 71
Anxiety 74
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019 74
Dementia 75
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019 75
Parkinson's disease 77
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019 77
Depression 78
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019 78
Personality/Psychiatric Disorders (Schizophrenia/bipolar) 79
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019 80
Spinal Cord Injury 80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019 81
Addiction Disorders 81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019 81
Attention Deficit Hyperactivity Disorder (ADHD) 82
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019 82
Sleep Disorders 83
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019 83
CHAPTER 4 COMPANY PROFILES 86
ABLYNX 86
ADENIOS 87
ANGIOCHEM 87
ARMAGEN TECHNOLOGIES 89
BIOASIS TECHNOLOGIES 90
BRISTOL-MYERS SQUIBB 91
CAPSULUTION PHARMA 92
DAINIPPON SUMITOMO PHARMA 93
ELI LILLY AND COMPANY 93
EUTHYMICS BIOSCIENCE 94
FABRE-KRAMER PHARMACEUTICALS 95
FLOCEL 95
FORUM PHARMACEUTICALS 96
GENZYME 97
INSIGHTEC 97
INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS) 98
ISIS INNOVATION 98
JANSSEN PHARMACEUTICA 99
H LUNDBECK 100
MEDGENESIS THERAPEUTIX (BIOVAIL LAB) 101
MEDIMMUNE 101
MEDINVENT 102
NANOMERICS 102
NEUROVIVE PHARMACEUTICAL 103
NEUREN PHARMACEUTICALS 103
NSGENE 104
OPTINOSE 106
OSSIANIX 106
OTSUKA AMERICA PHARMACEUTICAL 107
PROTHENA CORP 107
PROTHERAGEN 108
PFIZER 108
PHARMACO-CELL 109
PHARMIDEX 109
RAPTOR PHARMACEUTICAL 111
ROCHE 112
ROYALTY PHARMA 112
SHIRE 113
SANERON CCEL THERAPEUTICS 113
SOLVO BIOTECHNOLOGY 114
SOVICELL 115
TEVA PHARMACEUTICAL INDUSTRIES 115
TO-BBB TECHNOLOGIES 116
TTY BIOPHARM 117
UCB 118
VECT-HORUS 118
XENOPORT 119
XIGEN 120


LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
THROUGH 2019 ($ MILLIONS) 7
TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH
2017 ($ BILLIONS) 17
TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY,
2013 22
TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH
2019 (NUMBER OF UNITS COMMERCIALIZED) 26
TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE
CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION) 26
TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS) 27
TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY 44
TABLE 7 KEY BBB TECHNOLOGY PATENTS 48
TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS
ENDING 2013 54
TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH
PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS) 55
TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58
TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL
METHOD 59
TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING
DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET 61
TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB
TECHNOLOGIES 64
TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL
EFFECTS 67
TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019 71
TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019 74
TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019 75
TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019 77
TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019 78
TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019 80
TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019 81
TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019 81
TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER,
THROUGH 2019 82
TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019 83


LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS,
2012-2019 ($ MILLIONS) 7
FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND
2017 (PERCENT OF GLOBAL SALES) 18
FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO
THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS) 18
FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION,
2019* ($ MILLIONS) 19
FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY
THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS) 20
FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN
CLINICAL DEVELOPMENT, 2019* (%) 21
FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS) 24
FIGURE 7 PARTS OF THE BBB 31
FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS 32
FIGURE 9 METHODS OF CROSSING THE BBB 42
FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE,
2014* (% OF INDUSTRY) 56
FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE
COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET) 56
FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND
2019 (NUMBER OF UNITS) 58



To order this report: Blood-Brain Barrier Technologies and Global Markets
http://www.reportlinker.com/p0492943/Blood-Brain-Barrier-Technologies-and-Global-Markets.html



__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that CA Technologies has been named “Platinum Sponsor” of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business – from apparel to energy – is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
SYS-CON Events announced today that CAST Software will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CAST was founded more than 25 years ago to make the invisible visible. Built around the idea that even the best analytics on the market still leave blind spots for technical teams looking to deliver better software and prevent outages, CAST provides the software intelligence that matter ...
As more and more companies are making the shift from on-premises to public cloud, the standard approach to DevOps is evolving. From encryption, compliance and regulations like GDPR, security in the cloud has become a hot topic. Many DevOps-focused companies have hired dedicated staff to fulfill these requirements, often creating further siloes, complexity and cost. This session aims to highlight existing DevOps cultural approaches, tooling and how security can be wrapped in every facet of the bu...
yperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let’s say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it....
SYS-CON Events announced today that Pulzze Systems will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems Inc, provides the software product "The Interactor" that uniquely simplifies building IoT, Web and Smart Enterprise Solutions. It is a Silicon Valley startup funded by US government agencies, NSF and DHS to bring innovative solutions to market.
In his session at @ThingsExpo, Dr. Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, presented the findings of a series of six detailed case studies of how large corporations are implementing IoT. The session explored how IoT has improved their economic performance, had major impacts on business models and resulted in impressive ROIs. The companies covered span manufacturing and services firms. He also explored servicification, how manufacturing firms shift from se...
With Cloud Foundry you can easily deploy and use apps utilizing websocket technology, but not everybody realizes that scaling them out is not that trivial. In his session at 21st Cloud Expo, Roman Swoszowski, CTO and VP, Cloud Foundry Services, at Grape Up, will show you an example of how to deal with this issue. He will demonstrate a cloud-native Spring Boot app running in Cloud Foundry and communicating with clients over websocket protocol that can be easily scaled horizontally and coordinate...
SYS-CON Events announced today that Elastifile will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Elastifile Cloud File System (ECFS) is software-defined data infrastructure designed for seamless and efficient management of dynamic workloads across heterogeneous environments. Elastifile provides the architecture needed to optimize your hybrid cloud environment, by facilitating efficient...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, d...
Businesses and business units of all sizes can benefit from cloud computing, but many don't want the cost, performance and security concerns of public cloud nor the complexity of building their own private clouds. Today, some cloud vendors are using artificial intelligence (AI) to simplify cloud deployment and management. In his session at 20th Cloud Expo, Ajay Gulati, Co-founder and CEO of ZeroStack, discussed how AI can simplify cloud operations. He covered the following topics: why cloud mana...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
SYS-CON Events announced today that Golden Gate University will exhibit at SYS-CON's 21st International Cloud Expo®, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Since 1901, non-profit Golden Gate University (GGU) has been helping adults achieve their professional goals by providing high quality, practice-based undergraduate and graduate educational programs in law, taxation, business and related professions. Many of its courses are taug...
Vulnerability management is vital for large companies that need to secure containers across thousands of hosts, but many struggle to understand how exposed they are when they discover a new high security vulnerability. In his session at 21st Cloud Expo, John Morello, CTO of Twistlock, will address this pressing concern by introducing the concept of the “Vulnerability Risk Tree API,” which brings all the data together in a simple REST endpoint, allowing companies to easily grasp the severity of t...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale.